2023 Volume 23 Issue 3 Pages 114-118
The of BRCA1/2 gene test has widely used as a companion diagnostic for the PARP inhibitors to diagnose hereditary breast and ovarian cancer (HBOC). Resultingly, more cases will be diagnosed with BRCA1/2 mutations. Annual breast-enhanced magnetic resonance imaging (MRI) is recommended for BRCA1/2 mutation carriers, preferably in collaboration with a facility capable of MRI-guided vacuum-assisted biopsy (MRI-VAB). In Japan, there are only a few institutions that perform MRI-VAB as a medical treatment covered by insurance. MRI-VAB was started in June 2022 at our institution. From June 2022 to May 2023, six patients underwent MRI-VAB. The pathological findings were as follows: invasive ductal carcinoma in one case, ductal carcinoma in situ in two cases, and benign lesions in three cases. Of six, a woman with a BRCA2 gene mutation who was diagnosed with DCIS was included. We hope that the medical system will be developed so that high-risk women who require MRI-VAB can receive appropriate examinations.
